Powerfleet Reports Third Quarter 2025 Financial Results — Neutral
AIOT PRNewsWire — February 10, 2025Q3 revenue rises to $106 million, an increase of 45% year-over-year, with service revenuerepresenting 77% of total revenue Adjusted EBITDA climbs to $22 million, an increase of 77%, driving an annual run ratesurpassing $85 million— doubling 2024 adjusted EBITDA FY25 full year guidance increased $10 million for revenue and $2.5 million for adjustedEBITDA Meaningful increase in adjusted gross margin performance, with total adjusted grossmargins now above 60%, and adjusted service gross margins approaching 70% Post-M&A integration ahead of schedule, priming for double digit growth trajectory in FY26 WOODCLIFF LAKE, N.J. , Feb. 10, 2025 /PRNewswire/ -- Powerfleet, Inc. (Nasdaq: AIOT) …
Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation — Neutral
ATRA Accesswire — February 10, 2025NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA). Investors who purchased Atara securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ATRA.
SHOEMAKERSVILLE, Pa., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Hydrofarm Holdings Group, Inc. (Nasdaq: HYFM) (“Hydrofarm” or the “Company”) today announced that its Board of Directors has approved a 1-for-10 reverse stock split of the Company's common stock, par value $0.0001, which will be effective at 5:00 pm Eastern Time on February 12, 2025. The Company's common stock will continue to be traded on The Nasdaq Capital Market on a split-adjusted basis beginning on February 13, 2025, under the Company's existing trading symbol “HYFM.”
Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer — Neutral
IOVA GlobeNewsWire — February 10, 2025SAN CARLOS, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that Dan Kirby will join the Company's executive leadership team in the newly created role of Chief Commercial Officer, effective today.
Leading Proxy Advisory Firm Glass Lewis Joins ISS and Egan-Jones in Recommending Matthews International Shareholders Vote the GOLD Proxy Card "FOR" ALL of Barington Capital's Nominees: Ana Amicarella, Chan Galbato and James Mitarotonda — Neutral
MATW PRNewsWire — February 10, 2025Glass Lewis Finds Matthews Has "Persistently Deteriorated and Consistently Underperformed During Substantially All Measurement Periods, Including During the Fullness of Mr. Bartolacci's Tenure as CEO" Asserts Barington "Has Offered Investors a Reasonable, Credible and Incremental Slate of Candidates" and a "More Promising Roadmap" for the Company Recommends Shareholders Vote "WITHHOLD" on Matthews' Nominees Terry L.
McDONALD'S REPORTS FOURTH QUARTER AND FULL YEAR 2024 RESULTS — Neutral
MCD PRNewsWire — February 10, 2025Global Systemwide sales* were over $130 billion for the full year, with full year growth of more than $1 billion (more than $2 billion in constant currencies) Systemwide sales to loyalty members were approximately $30 billion for the full year and approximately $8 billion for the quarter across 60 loyalty markets, with full year growth of 30% over prior year 90-day active loyalty users were over 175 million across 60 loyalty markets as of year-end, with growth of approximately 15% over prior year CHICAGO , Feb. 10, 2025 /PRNewswire/ -- McDonald's Corporation today announced results for the fourth quarter and …
Beamr CEO will Present a Keynote Speech at the ACM Mile-High-Video 2025 — Neutral
BMR GlobeNewsWire — February 10, 2025The Keynote Titled ״Is the future of video processing destined for GPU?״ Describes First Hand The Evolution of Video Encoding in the Past Decades Herzliya Israel, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Beamr Imaging Ltd.
Up to 70% Time Savings Achieved with Fully Integrated Advanced Referral Module of CareCloud's AI-Enabled EHR — Neutral
CCLD GlobeNewsWire — February 10, 2025Streamlining the Referral Process to Enhance Efficiency and Patient Experience SOMERSET, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDO, CCLDP), a leader in healthcare technology and AI-driven solutions, is proud to announce the launch of its new advanced referral module.
Ispire Technology Inc. Reports Financial Results for Fiscal Second Quarter 2025 — Neutral
ISPR PRNewsWire — February 10, 2025Gross Profit Increased 23.5% from the Previous Year to $7.7 million Gross Margins Increased to 18.5%, up from 15.0% the Previous Year Revenue Increased 0.3% Year-Over-Year to $41.8 Million LOS ANGELES , Feb. 10, 2025 /PRNewswire/ -- Ispire Technology Inc. ( NASDAQ: ISPR ) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported results for the fiscal second quarter 2025, which ended on December 31, 2024. Fiscal Second Quarter 2025 Financial Results Revenue of $41.8 million, compared to $41.7 million for the fiscal second quarter of 2024.
MU INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Micron Technology, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! — Neutral
MU Accesswire — February 10, 2025NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Micron Technology, Inc. ("Micron" or "the Company") (NASDAQ:MU) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Micron securities between September 28, 2023 and December 18, 2024, both dates inclusive (the "Class Period").
PSNY SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Polestar Automotive Holding UK PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! — Neutral
PSNY Accesswire — February 10, 2025NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Polestar Automotive Holding UK PLC ("Polestar" or "the Company") (NASDAQ:PSNY) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Polestar securities between November 14, 2022 and January 16, 2025, both dates inclusive (the "Class Period").
KSPI SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Joint Stock Company Kaspi.kz Investors Have Opportunity to Lead Class Action Lawsuit! — Neutral
KSPI Accesswire — February 10, 2025NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Joint Stock Company Kaspi.kz ("Kaspi.kz" or "the Company") (NASDAQ:KSPI) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Kaspi.kz securities between January 19, 2024 and September 19, 2024, both dates inclusive (the "Class Period").
APLT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Applied Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! — Neutral
APLT Accesswire — February 10, 2025NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Applied Therapeutics, Inc. ("Applied Therapeutics" or "the Company") (NASDAQ:APLT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Applied Therapeutics securities between January 3, 2024 and December 2, 2024, both dates inclusive (the "Class Period").
SHANGHAI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- ECARX Holdings, Inc. (Nasdaq: ECX) (“ECARX” or the “Company”), a global mobility tech provider, today announced a significant upgrade to its ECARX AutoGPT in-vehicle AI large model application with the integration of the DeepSeek-R1 model, resulting in a faster, more secure, and more personalized user experience. This advancement expands AutoGPT's local processing capabilities and enhances its reasoning and decision-making abilities for automotive-specific application scenarios.
Tower Semiconductor Reports 2024 Fourth Quarter and Full Year Financial Results — Neutral
TSEM GlobeNewsWire — February 10, 2025MIGDAL HAEMEK, Israel, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Tower Semiconductor (NASDAQ: TSEM & TASE: TSEM) reports today its results for the fourth quarter of 2024 and for the year ended December 31, 2024.
FINAL REMINDER SUI DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Sun Communities, Inc. Investors to Participate in the Class Action Lawsuit — Neutral
SUI Accesswire — February 10, 2025NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sun Communities, Inc. ("Sun Communities" or "the Company") (NYSE:SUI) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sun Communities securities between February 28, 2019 and September 24, 2024, both dates inclusive (the "Class Period").
DMC Global Acknowledges Non-Binding Proposal from Steel Connect — Neutral
BOOM GlobeNewsWire — February 10, 2025BROOMFIELD, Colo., Feb. 10, 2025 (GLOBE NEWSWIRE) -- DMC Global Inc. (Nasdaq: BOOM) (“DMC” or the “Company”) today acknowledged receipt of a non-binding proposal from Steel Connect to acquire all of the outstanding shares of common stock of the Company, not already owned by Steel Connect, for $10.18 per share in cash (the “Proposal”).
With No Competing Offers, Beacon Roofing's Board Stalls and Misleads — Neutral
QXO GlobeNewsWire — February 10, 2025Beacon Insiders Recently Sold Shares Well Below Offer Price, Undermining Beacon's Case Against QXO QXO Calls on Beacon Roofing to Let Shareholders Decide on QXO's $124.25 All-Cash Offer GREENWICH, Conn., Feb. 10, 2025 (GLOBE NEWSWIRE) -- QXO, Inc. (NYSE: QXO) today released a letter to Beacon Roofing Supply, Inc. shareholders regarding its $124.25 per share all-cash offer, addressing misrepresentations in Beacon's recent 14D-9 filing.
FINAL ENPH DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Enphase Energy, Inc. Investors to Join the Class Action Lawsuit — Neutral
ENPH Accesswire — February 10, 2025NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Enphase Energy, Inc. ("Enphase" or "the Company") (NASDAQ:ENPH) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Enphase securities between April 25, 2023 and October 22, 2024, both dates inclusive (the "Class Period").
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update — Neutral
ROIV GlobeNewsWire — February 10, 2025BASEL, Switzerland and LONDON and NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the third quarter ended December 31, 2024, and provided a business update. Brepocitinib to be developed in third indication, cutaneous sarcoidosis (CS), an orphan indication with high unmet need; Phase 2 study initiation expected in second quarter of calendar year with topline data in second half of calendar year 2026 IMVT-1402 development is rapidly progressing with six Investigational New Drug (IND) applications cleared and pivotal studies in Graves' disease (GD) and difficult-to-treat rheumatoid arthritis (D2T RA) initiated Batoclimab …